KALA BIO Secures Highly Dilutive $4.2M Financing, Approves Reverse Split & Board Overhaul Amid Distress

summarizeSummary

KALA BIO secured $4.2 million in highly dilutive financing and received shareholder approval for a reverse stock split to address Nasdaq non-compliance, alongside a significant board restructuring.

check_boxKey Events

• Secures $4.2 Million in Highly Dilutive Financing

  KALA BIO completed the second closing of a private placement, issuing 2.1 million shares of Series AAA Preferred Stock at $2.00 per share for aggregate gross proceeds of $4.2 million. Each Series AAA share is convertible into 420 common shares, totaling 882 million common shares at a deeply discounted conversion price of $0.00476, representing extreme dilution for existing shareholders.

• Shareholders Approve Massive Share Increase

  Stockholders approved an amendment to increase the number of authorized common shares to 1.5 billion, a necessary step to accommodate the significant dilution from the conversion of Series AA and Series AAA Preferred Stock.

• Shareholders Approve Reverse Stock Split

  Stockholders approved a reverse stock split at a ratio of not less than 1-for-2 and not greater than 1-for-100, at the Board's discretion. This action directly addresses the Nasdaq non-compliance notice received on January 23, 2026, regarding the minimum bid price rule.

• Significant Board Overhaul Completed

  Six directors resigned, and five new directors were appointed by the Board upon the recommendation of the Nominating and Corporate Governance Committee, following the approval of the Issuance and Share Increase Proposals and the Second Closing of the private placement, indicating a shift in corporate control.

auto_awesomeAnalysis

This 8-K details critical actions taken by KALA BIO to address its severe financial distress and Nasdaq listing challenges. The company completed the second closing of a private placement, raising $4.2 million by issuing Series AAA Preferred Stock convertible into an astronomical 882 million common shares at a deeply discounted conversion price of $0.00476, representing extreme dilution for existing shareholders. This financing, while providing a lifeline, comes at a substantial cost. Concurrently, shareholders approved a massive increase in authorized common stock to 1.5 billion shares to accommodate this dilution and also approved a reverse stock split, a necessary step to regain compliance with Nasdaq's minimum bid price rule following a recent deficiency notice. The filing also reports a significant overhaul of the board of directors, with six previous directors resigning and five new directors appointed by the investor group, signaling a shift in corporate control. Investors should note the severe dilution and the company's ongoing struggle for financial viability and listing compliance.